For the Inventor, By the Inventor

Enter inventor name

Masatoshi Hagiwara

USPTO Granted Patents = 18 (Patent Applications = 13)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 56(Granted Patents)

Location History:

Nogoya, JP (1992)
Nagoya, JP (1993)
Chiba-shi, Chiba JP (2009)
Tokyo, JP (2010 - 2011)
Chiba, JP (2012 - 2014)
Kyoto, JP (2016 - 2024)

Company Filing History:

Kyoto University

Kinopharma, Inc.

Tobishi Yakuhin Kogyo Kabushiki Kaisha

4. 2 out of 130

Tokyo Medical and Dental University

Kagoshima University

Masatoshi Hagiwara

7. 6 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2024

Loading Chart...

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12138253 - Tumor suppression (2024-11-12),

2. 12023338 - Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities (2024-07-02),

3. 11318126 - Composition for activating neurogenesis (2022-05-03),

4. 10017524 - Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor (2018-07-10),

5. 9879014 - Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease (2018-01-30),

6. 9745323 - Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor (2017-08-29),

7. 9745275 - Pain-related compound and medical composition (2017-08-29),

8. 9273364 - Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms (2016-03-01),

9. 9241929 - Prophylactic or ameliorating agent for genetic diseases (2016-01-26),

10. 8816089 - Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity (2014-08-26),

11. 8765941 - Aniline derivative having anti-RNA viral activity (2014-07-01),

12. 8338362 - Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity (2012-12-25),

13. 7928283 - Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in nematodes (2011-04-19),

14. 7786151 - Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction (2010-08-31),

15. 7569536 - Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity (2009-08-04),

Title: Masatoshi Hagiwara: Pioneer in Tumor Suppression and Genetic Disease Treatments

Introduction

Masatoshi Hagiwara, a notable inventor based in Kyoto, Japan, has made significant contributions to the fields of medicine and molecular biology. With a remarkable portfolio of 18 patents, Hagiwara's innovations are focused on combating tumor viruses and tackling genetic diseases linked to splicing abnormalities.

Latest Patents

Among Hagiwara's latest patents is a groundbreaking method for tumor suppression. This patent outlines a method designed to prevent, ameliorate, suppress the progression of, and treat tumors that are caused by tumor viruses. The method involves administering an effective amount of a component that specifically targets a gene product of the tumor virus.

In addition, he has developed a pharmaceutical composition and treatment method for genetic diseases associated with splicing abnormalities. This invention offers a pharmaceutical composition aimed at preventing and treating genetic diseases stemming from aberrant splicing regulation. The composition includes compounds that can suppress the aberrant splicing regulation that contributes to the development or progression of these genetic disorders.

Career Highlights

Hagiwara has had a distinguished career, particularly through his work with Kyoto University. His research has led to significant advancements in understanding genetic diseases and the mechanisms of tumor suppression, making him a respected figure in the scientific community.

Collaborations

Throughout his career, Masatoshi Hagiwara has collaborated with esteemed colleagues including Takamitsu Hosoya and Masaaki Suzuki. These partnerships have further enriched his research and development processes, leading to innovative solutions that have the potential to impact many lives.

Conclusion

In summary, Masatoshi Hagiwara stands out as a leading inventor whose work in tumor suppression and genetic diseases reflects a dedication to advancing medical science. His extensive patent portfolio showcases his innovative approach and commitment to improving health outcomes through technological advancements.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…